US 12,290,522 B2
Method of treating amyotrophic lateral sclerosis
Thomas Macallister, Arlington, VA (US); and Sven Jacobson, New York, NY (US)
Assigned to Woolsey Pharmaceuticals, Inc., St. Petersburg, FL (US)
Filed by Woolsey Pharmaceuticals, Inc., St. Petersburg, FL (US)
Filed on Sep. 7, 2023, as Appl. No. 18/462,488.
Application 18/462,488 is a continuation of application No. 17/502,507, filed on Oct. 15, 2021, granted, now 11,779,588.
Prior Publication US 2023/0414633 A1, Dec. 28, 2023
Int. Cl. C07D 401/12 (2006.01); A61K 31/551 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/551 (2013.01) [A61P 25/28 (2018.01)] 22 Claims
 
1. A method of treating a patient with possible, probable laboratory-supported, probable, or definite sporadic amyotrophic lateral sclerosis (ALS), as defined by El Escorial Revised ALS diagnostic criteria, comprising orally administering a therapeutically effective amount of fasudil, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective dose of fasudil is 90 mg/day or higher.